<DOC>
	<DOCNO>NCT02605460</DOCNO>
	<brief_summary>The purpose study evaluate disease free survival overall survival patient acute leukemia first second complete remission administrate CXCR4 antagonist , chemo sensitization strategy , plus chemotherapy conditioning regimen autologous allogeneic hematopoietic stem cell transplantation ( HSCT ) .</brief_summary>
	<brief_title>Chemo Sensitization Before Hematopoietic Stem Cell Transplantation Patients With Acute Leukemia Complete Remission</brief_title>
	<detailed_description>In last decade , HSCT become efficient strategy treatment many malignant non-malignant hematological disease , common , accord European Bone Marrow Transplantation ( EBMT ) , acute leukemia . Both myeloid lymphoid acute leukemia consider malignant clonal disease hematopoietic stem cell , represent therapeutic challenge due high relapse rate mortality use conventional chemotherapy regimen . HSC reside mainly within bone marrow , protect microenvironment niche , perivascular , create partly mesenchymal stromal cell endothelial cell . Interactions cell many adhesion molecule consider key factor grow , transformation , migration neoplastic cell . The main pathway involve cellular transit regulation chemokine receptor 4 ( CXCR4 ) chemokine ligand 12 ( CXCL12 ) , responsible mediating interaction HSC stromal cell , whose block cytokine antagonist CXCR4 receptor ( plerixafor ) favor chemotaxis HSC output peripheral blood . Such strategy become effective technique increase mobilization harvest patient undergoing stem cell transplantation . On hand , preclinical study show activation CXCL12 pathway favor tumor growth , promote survival invasion malignant cell , recruit stromal cell facilitate proliferation promote angiogenesis directly . In way , pathway consider therapeutic target block activity inhibit tumor progression . Patients acute leukemia first second complete remission undergo autologous allogeneic hematopoietic stem cell transplantation ( HSCT ) , commonly present low response rate low survival due persistent minimal residual disease , despite conventional high dose chemotherapy regimens . It necessary create strategy increase destruction rate neoplastic cell patient acute leukemia candidate HSCT . Our hypothesis administration CXCR4 antagonist part condition regimen patient acute leukemia candidate HSCT allow mobilization sensitization leukemia blast cell , eradicate efficiently minimal residual disease , responsible posterior relapse , achieve high response rate survival patient undergoing procedure .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Diagnosis AML ALL , candidate HSCT Allogeneic HSCT : High risk AML first complete remission ( CR ) , AML second CR , ALL first second CR match halfmatched ( haploidentical ) relate unrelated donor Autologous HSCT : Intermediate risk AML first CR , ALL first second CR without donor Normal liver function enzyme test Preserved renal function ECOG ≤2 oR Karnofsky ≥80 % FEVI &gt; 40 % Hb ≥ 10 g/dl , Absolute Neutrophil Count ≥ 1 x 103/mm3 , Platelets ≥ 100,000 /µL Signed Informed Consent Patients willing participate sign inform consent Patients meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Conditioning Regimen</keyword>
</DOC>